CM Life Sciences III (NASDAQ:CMLT) announced this morning that its shareholders approved its combination with biotech firm EQRx in a special meeting yesterday.
The 8-K did not disclose redemption figures but, CM III went into the vote with at least some risk having traded below $10 since August. Following close, the combined company is expected to trade on the Nasdaq under the symbol “EQRX”
CM Life Sciences III initially announced the $3.54 billion combination with EQRx on August 6. Cambridge, Massachusetts-based EQRx is developing a range of drug candidates both generated in-house and licensed from peers with an aim to reducing the overall cost of pharmaceutical rollouts.
All measures on the company’s ballot passed by large margins, but some received dissenting votes amounting to about 19% of participating shares. For full vote tallies, click here.
ADVISORS
- J.P. Morgan Securities, LLC is acting as the lead financial advisor, with Goldman Sachs & Co. LLC also acting as a financial advisor.
- PJT Partners LP is also acting as a financial advisor and Goodwin Procter LLP is serving as the legal advisor to EQRx.
- Jefferies LLC and Cowen and Company, LLC are acting as joint capital markets advisors.
- White & Case LLP is serving as legal advisor to CM Life Sciences III.
- Jefferies LLC, Cowen and Company, LLC and J.P. Morgan Securities LLC are acting as joint placement agents.
Terms Tracker for the Week Ending January 17, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We may be heading into a Polar Vortex, but SPACs managed to generate some heat this week with three more IPOs. For those keeping count,...
Giving internet users a place to chat or post pictures of their lunch has never been an especially profitable endeavor until social media platforms gain the scale to leverage user data en masse like Meta (NASDAQ:META). But, the addition of retail investor appetites to the equation has suddenly turned even smaller platforms into a tantalizing...
At the SPAC of Dawn This week comes to a close with the debut of the year’s fourth SPAC IPO as Hennessy Capital Investment Corp. VII (NASDAQ:HVIIU) priced last night. This brings the month’s total IPO proceeds to $597.5 million, which is already a drastic year-on-year improvement from January 2023, which saw just $144 million...
Hennessy Capital Investment Corp. VII (NASDAQ:HVIIU) announced the pricing of its $175 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “HVIIU”, Friday, January 17, 2025. The new SPAC intends to seek out a business combination with a company in the industrial technology and energy transition sectors. Hennessy...
Equites and crytpo trading platform eToro has reportedly filed for a traditional IPO two-and-half years after nixing its SPAC combination and its renewed thrust to the public markets could provide a useful demonstration of where things sit for SPACs in 2025. For one, eToro is reportedly making its IPO move at a valuation of $5...